Regimens Set to Overtake Monotherapies in Total Immuno-Oncology (IO) Sales

ASCO’s Annual Meeting has once again shown how important combinations of novel therapies with established regimens are for expanding into earlier lines or other indications, especially as a drug’s market matures and it chases harder to reach patient pools. Immuno-oncology (IO) drugs have shown rapid growth through repeated success following this strategy, as they chase multiple indications.